Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
JAMA dermatology - 156(2020), 6 vom: 01. Juni, Seite 708-710 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Piccerillo, Alfredo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.02.2021 Date Revised 18.02.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamadermatol.2020.0304 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309044464 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309044464 | ||
| 003 | DE-627 | ||
| 005 | 20231225133041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamadermatol.2020.0304 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309044464 | ||
| 035 | |a (NLM)32320041 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Piccerillo, Alfredo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.02.2021 | ||
| 500 | |a Date Revised 18.02.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 650 | 7 | |a COL7A1 protein, human |2 NLM | |
| 650 | 7 | |a Collagen Type VII |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Thyroxine |2 NLM | |
| 650 | 7 | |a Q51BO43MG4 |2 NLM | |
| 700 | 1 | |a El Hachem, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a De Vito, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Erika Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, Ketty |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA dermatology |d 2013 |g 156(2020), 6 vom: 01. Juni, Seite 708-710 |w (DE-627)NLM221849696 |x 2168-6084 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2020 |g number:6 |g day:01 |g month:06 |g pages:708-710 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamadermatol.2020.0304 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2020 |e 6 |b 01 |c 06 |h 708-710 | ||